KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.97

Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.

K Kalinsky, S A Wander, E Hamilton, S L Graff, R Jeselsohn, K H Park, U Demirci, M Martin, R M Layman, S A Hurvitz, S Sammons, P A Kaufman, E Ravenberg, S Amdur, L M Litchfield, G Bianchini

Ann Oncol S0923-7534(26)08075-0

PMID42926108
PMCID-
DOI10.1016/j.annonc.2026.10.1283
发表日期2026-10-24
入排依据:Eligible: phase III randomized oncology drug trial reporting final overall survival time-to-event results.
摘要

摘要

BACKGROUND: The phase III postMONARCH trial demonstrated a statistically significant improvement in progression-free survival (PFS) with abemaciclib plus fulvestrant versus placebo plus fulvestrant in participants with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) after disease progression on prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET). Here, we report the prespecified final overall survival (OS) analysis. PARTICIPANTS AND METHODS: Eligible patients had disease progression on a CDK4/6i plus aromatase inhibitor as initial therapy for ABC or recurrence on or after adjuvant CDK4/6i plus ET. Participants were randomly assigned 1 : 1 to receive abemaciclib plus fulvestrant or placebo plus fulvestrant. The final OS analysis was prespecified at 200 OS events (HR boundary 0.753). Time-to-event analyses used the Kaplan-Meier method, and stratified Cox models were used to estimate the HR and 95% confidence intervals (CIs). RESULTS: A total of 368 participants were randomly assigned 1 : 1 to abemaciclib plus fulvestrant (n = 182) or placebo plus fulvestrant (n = 186). At data cut-off, the median follow-up was ∼37 months; 200 OS events were observed [90 (50%) versus 110 (59%)]. Median OS was 32.1 months with abemaciclib plus fulvestrant versus 24.6 months with placebo plus fulvestrant (HR 0.80, 95% CI 0.60-1.06, P = 0.11, boundary for significance not reached). OS differences were consistent across subgroups. Updated PFS was consistent with the primary analysis (HR 0.78, 95% CI 0.62-0.99, nominal P = 0.039). Time to secondly progression and chemotherapy-free survival also favored abemaciclib plus fulvestrant. Safety was consistent with the established abemaciclib profile with no new signals identified. CONCLUSION: Abemaciclib plus fulvestrant resulted in a numerically longer median OS versus placebo plus fulvestrant, although statistical significance was not reached. The totality of evidence supports the consideration of abemaciclib-based treatment of patients with hormone receptor-positive, HER2-negative ABC after disease progression on prior CDK4/6i plus ET.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。